TopGum adjusted EBITDA more than doubles to $5.3 million in Q1 FY26; revenue rises 85% to $31.9 million

  • TopGum Q1 2026 revenue climbed 85% from a year earlier to $31.9 million, led by dietary supplements rising 162% to $25.8 million.
  • Adjusted EBITDA more than doubled to $5.3 million; margin widened 2 percentage points to 17%.
  • Net income rose to $3.4 million from a year earlier, while dietary supplements backlog for the next 4-5 months reached $52 million.
  • Confectionery revenue in Israel fell 18% to $6.1 million, citing the “Lion’s Roar” operation and tougher local competition.
  • Completed the acquisition of P&L Developments’ U.S. gummy manufacturing operations, adding a U.S. footprint and entry into pharmaceutical gummies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Top Gum Industries Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605260828PR_NEWS_USPR_____LN67677) on May 26, 2026, and is solely responsible for the information contained therein.